However, for HR+ breast cancer patients, compared to patients with triple-negative or HER2+ tumors, the benefit of NAC in terms of pCR is limited, as pCR to neoadjuvant treatment is observed less frequently in HR+ patients [7, 8]. The gene discussed is ERBB2; the disease is breast carcinoma.